MX2021008249A - Fragmentos de defensina para su uso en tratamientos o profilaxis. - Google Patents

Fragmentos de defensina para su uso en tratamientos o profilaxis.

Info

Publication number
MX2021008249A
MX2021008249A MX2021008249A MX2021008249A MX2021008249A MX 2021008249 A MX2021008249 A MX 2021008249A MX 2021008249 A MX2021008249 A MX 2021008249A MX 2021008249 A MX2021008249 A MX 2021008249A MX 2021008249 A MX2021008249 A MX 2021008249A
Authority
MX
Mexico
Prior art keywords
prophylaxis
therapy
defensin
fragments
defensin fragments
Prior art date
Application number
MX2021008249A
Other languages
English (en)
Inventor
Jan Wehkamp
Dirk Ehmann
Original Assignee
Aesculus Bio Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aesculus Bio Aps filed Critical Aesculus Bio Aps
Publication of MX2021008249A publication Critical patent/MX2021008249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con nuevos péptidos derivados de HD-5 o HNP-4 que tienen actividad antimicrobiana para su uso en la modulación del microbioma de los intestinos, los pulmones, la piel, la boca, los ojos, los oídos, la vagina u otras superficies del cuerpo y/o para su uso como un agente antimicrobiano en un ser humano u otros mamíferos, así como medicamentos que contengan estos péptidos.
MX2021008249A 2019-01-07 2020-01-07 Fragmentos de defensina para su uso en tratamientos o profilaxis. MX2021008249A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102019100230 2019-01-07
DE102019108626 2019-04-02
PCT/EP2020/050186 WO2020144166A1 (en) 2019-01-07 2020-01-07 Defensin fragments for use in therapy or prophylaxis

Publications (1)

Publication Number Publication Date
MX2021008249A true MX2021008249A (es) 2021-10-13

Family

ID=69167795

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008249A MX2021008249A (es) 2019-01-07 2020-01-07 Fragmentos de defensina para su uso en tratamientos o profilaxis.

Country Status (11)

Country Link
US (1) US20220064217A1 (es)
EP (1) EP3908305A1 (es)
JP (1) JP7479381B2 (es)
KR (1) KR20210126585A (es)
CN (1) CN113453701A (es)
AU (1) AU2020207527A1 (es)
BR (1) BR112021013434A2 (es)
CA (1) CA3125689A1 (es)
MX (1) MX2021008249A (es)
SG (1) SG11202107310RA (es)
WO (1) WO2020144166A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114456232B (zh) * 2021-11-09 2023-09-29 中国科学院动物研究所 抑制饮食性肥胖的药物及其所用多肽
KR20230122899A (ko) * 2022-02-15 2023-08-22 주식회사 나이벡 항균, 항염증 또는 조직재생능을 구비하는 펩타이드 및 이의 용도
CN117304297B (zh) * 2023-10-18 2024-05-31 河南大学 一种重组人α-防御素5及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US20190111107A1 (en) * 2016-01-26 2019-04-18 Defensin Therapeutics Aps Methods for modulating intestinal microbiota
WO2017186250A1 (en) 2016-04-29 2017-11-02 Defensin Therapeutics Aps Treatment of liver, biliary tract and pancreatic disorders
BR112019011844A2 (pt) 2016-12-13 2022-05-10 Defensin Therapeutics Aps Uso de pelo menos uma defensina

Also Published As

Publication number Publication date
US20220064217A1 (en) 2022-03-03
BR112021013434A2 (pt) 2021-10-19
EP3908305A1 (en) 2021-11-17
SG11202107310RA (en) 2021-08-30
WO2020144166A1 (en) 2020-07-16
KR20210126585A (ko) 2021-10-20
JP2022517764A (ja) 2022-03-10
AU2020207527A1 (en) 2021-08-19
CN113453701A (zh) 2021-09-28
JP7479381B2 (ja) 2024-05-08
CA3125689A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2021008249A (es) Fragmentos de defensina para su uso en tratamientos o profilaxis.
SA521421897B1 (ar) تركيبة تعتمد على جزء من نباتات طبية أو مستخلصاتها واستخداماتها ومنتجاتها
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
MX2020007049A (es) Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus.
MX2019015741A (es) Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1.
WO2020242896A3 (en) Treatment of angiopoietin like 7 (angptl7) related diseases
MX2023006611A (es) Acido hidroxiestearico para inducir la generacion de peptidos antimicrobianos.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2023000398A (es) Analogos de insulina novedosos y usos de estos.
MX338323B (es) Formulacion topica oftalmica de peptidos.
EP4021369A4 (en) MEDICAL DEVICES FOR CONTINUOUS DELIVERY OF THERAPEUTIC AGENTS
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
MX2021011491A (es) Polvos secos inhalables.
MX2019011951A (es) Secretoma bacteriano para usarse en el tratamiento contra lesiones cutaneas.
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
MX2019002894A (es) Combinaciones con un peptido ciclado con la estructura de la base.
MX2021003123A (es) Isomeros rotomericos de 4-alquil-5-heteroaril-3h-1,2-ditiol-3-tion as.
MX366997B (es) Combinaciones con un peptido con esqueleto ciclado.
MX2024000757A (es) Variantes recombinantes de proteínas r-espondina y uso de las mismas.
WO2022092907A3 (ko) 다부위에 적용가능한 플라즈마 치료기
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
CA3156680A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME
WO2022023533A3 (en) Antiviral use of liraglutide and gefitinib